Vistagen Therapeutics (VTGN) Return on Capital Employed (2012 - 2026)
Vistagen Therapeutics (VTGN) posted Return on Capital Employed of 163.85% for Q1 2026, down 39.39% sequentially from 117.55% in Q4 2025, and down 8992.0% YoY from 1.84% in Q1 2025.
Vistagen Therapeutics (VTGN) Return on Capital Employed (2012 - 2026) Analysis & Trends
Vistagen Therapeutics has reported Return on Capital Employed for 12 years, with the latest figure at 163.85% in Q1 2026.
- Quarterly Return on Capital Employed fell 8992.0% year-over-year to 163.85% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 163.85% (down 8992.0% YoY) and the FY2026 annual result came in at 134.42%, down 7317.0% from the prior year.
- Return on Capital Employed declined to 163.85% in Q1 2026 per VTGN's latest filing, from 117.55% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 27.01% in Q1 2024 and troughed at 331.82% in Q2 2023.
- A 5-year average of 119.77% and a median of 103.54% in 2022 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed sank 22828 bps in 2023, then surged 29786 bps in 2024.
- Over 5 years, Return on Capital Employed stood at 206.1% in 2022, then jumped by 80 bps to 41.11% in 2023, then plunged by 46 bps to 60.19% in 2024, then plunged by 95 bps to 117.55% in 2025, then slumped by 39 bps to 163.85% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 163.85%, 117.55%, and 106.84% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 26.09% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -50.93% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 7.88% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -6.85% |
| 10 | Vistagen Therapeutics | 10.35 Mn | 10.35 Mn | - | -225.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -163.85% |
| Dec 31, 2025 | -117.55% |
| Sep 30, 2025 | -106.84% |
| Jun 30, 2025 | -91.09% |
| Mar 31, 2025 | -73.93% |
| Dec 31, 2024 | -60.19% |
| Sep 30, 2024 | -45.37% |
| Jun 30, 2024 | -33.96% |
| Mar 31, 2024 | -27.01% |
| Dec 31, 2023 | -41.11% |
| Sep 30, 2023 | -139.21% |
| Jun 30, 2023 | -331.82% |
| Mar 31, 2023 | -284.60% |
| Dec 31, 2022 | -206.10% |
| Sep 30, 2022 | -147.69% |
| Jun 30, 2022 | -103.54% |
| Mar 31, 2022 | -62.19% |
| Dec 31, 2021 | -41.87% |
| Sep 30, 2021 | -34.01% |
| Jun 30, 2021 | -22.60% |